Value
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.9 |
| P/S | 9.8 |
| EV/EBITDA | 7.7 |
| Fwd P/E | 9.1 |
| PEG | 2.7 |
| Analyst target | 6.0 |
- ▸Forward P/E: 11.5x
- ▸PEG: 4.72
- ▸Attractively valued
THC · Why this verdict
Why Tenet Healthcare (THC) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analyst consensus targets imply 22.4% upside from the current price of $179.11 to a take-profit of $219.26, with a confirmed favorable reward-to-risk ratio of 1.86x and a 38% margin of safety noted in the bull case — the only stock in this batch that fully passed all investment gates. Targets | Stock price reaching at least $200, more than 11% above current $179.11, within the next 12 months would represent early progress toward realizing the full analyst target upside. | →Stable |
| CounterThe stock is currently below its 200-day moving average in a death-cross recovery pattern, and even with all gates passed the technical setup labeled RECOVERY implies the stock has yet to regain full price momentum. | ||
Tenet Healthcare beat earnings estimates in all 4 of the last 4 quarters with individual surprises of 15.7%, 15.6%, 10.5%, and 40.1%, averaging over 20% above consensus — one of the most consistent outperformance records in the hospital sector. Earnings | Positive earnings surprise above 10% in each of the next 2 reported quarters would confirm the outperformance pattern is structural and not driven by one-quarter anomalies. | →Stable |
| CounterThe 40.1% beat in July 2025 was unusually large and may have been driven by one-time items, making the true underlying beat cadence closer to the more modest 10-16% seen in other quarters. | ||
With 70% of revenue from managed care payers and 69% from just the top 10 managed care organizations, Tenet is highly exposed to contract renegotiations, reimbursement rate cuts, or network exclusions by any of its largest customers. Bear case | Revenue from managed care payers declining as a proportion to below 60% through diversification into government payers or direct-pay patients over the next 12 months would reduce the single-counterparty concentration risk. | →Stable |
| CounterManaged care concentration is industry-standard for large hospital systems, and Tenet's scale and market position in key geographic markets gives it negotiating leverage that smaller providers lack. | ||
Tenet converts 180% of net income into free cash flow and achieves a 30% return on equity, demonstrating that the hospital business generates real economic cash well in excess of accounting profits — a characteristic of businesses with favorable working capital dynamics and asset-light components. Quality | Free cash flow conversion remaining above 120% of net income over the next 4 reported quarters would confirm the cash generation quality is structural to the hospital segment operating model. | →Stable |
| CounterHigh free cash flow relative to net income at a hospital company can reflect elevated depreciation of medical equipment and facilities that will require reinvestment, temporarily overstating available cash. | ||
Analyst consensus targets imply 22.4% upside from the current price of $179.11 to a take-profit of $219.26, with a confirmed favorable reward-to-risk ratio of 1.86x and a 38% margin of safety noted in the bull case — the only stock in this batch that fully passed all investment gates.
→StableTargets
- Expectation
- Stock price reaching at least $200, more than 11% above current $179.11, within the next 12 months would represent early progress toward realizing the full analyst target upside.
CounterThe stock is currently below its 200-day moving average in a death-cross recovery pattern, and even with all gates passed the technical setup labeled RECOVERY implies the stock has yet to regain full price momentum.
Tenet Healthcare beat earnings estimates in all 4 of the last 4 quarters with individual surprises of 15.7%, 15.6%, 10.5%, and 40.1%, averaging over 20% above consensus — one of the most consistent outperformance records in the hospital sector.
→StableEarnings
- Expectation
- Positive earnings surprise above 10% in each of the next 2 reported quarters would confirm the outperformance pattern is structural and not driven by one-quarter anomalies.
CounterThe 40.1% beat in July 2025 was unusually large and may have been driven by one-time items, making the true underlying beat cadence closer to the more modest 10-16% seen in other quarters.
With 70% of revenue from managed care payers and 69% from just the top 10 managed care organizations, Tenet is highly exposed to contract renegotiations, reimbursement rate cuts, or network exclusions by any of its largest customers.
→StableBear case
- Expectation
- Revenue from managed care payers declining as a proportion to below 60% through diversification into government payers or direct-pay patients over the next 12 months would reduce the single-counterparty concentration risk.
CounterManaged care concentration is industry-standard for large hospital systems, and Tenet's scale and market position in key geographic markets gives it negotiating leverage that smaller providers lack.
Tenet converts 180% of net income into free cash flow and achieves a 30% return on equity, demonstrating that the hospital business generates real economic cash well in excess of accounting profits — a characteristic of businesses with favorable working capital dynamics and asset-light components.
→StableQuality
- Expectation
- Free cash flow conversion remaining above 120% of net income over the next 4 reported quarters would confirm the cash generation quality is structural to the hospital segment operating model.
CounterHigh free cash flow relative to net income at a hospital company can reflect elevated depreciation of medical equipment and facilities that will require reinvestment, temporarily overstating available cash.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Tenet Healthcare passed all required investment gates with a 22.4% upside to analyst targets and a favorable 1.86x reward-to-risk ratio, backed by a 4-of-4 earnings beat streak averaging 20.5% above consensus and a free cash flow conversion of 180% of net income — though managed-care payer concentration in 70% of revenue creates a key single-counterparty risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 5.2 |
| Gross margin | 4.3 |
| Op margin | 7.2 |
| Net margin | 4.0 |
| Current ratio | 5.1 |
| FCF quality | 10.0 |
| Moat | 5.6 |
| Piotroski F | 7.8 |
- ▸Excellent ROE: 30%
- ▸Excellent cash conversion: 180% FCF/NI
- ▸Strong Piotroski F-Score: 7/9
Growth
6.6/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.2 |
| EPS growth | 10.0 |
Momentum
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 6.9 |
- ▸Overbought (RSI 77)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 77 (late-cycle distribution risk)
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.5 |
| Analyst rating | 9.0 |
| Price target | 7.6 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Insider selling (low materiality) — $1,515,970 (0.009% of mkt cap)
Peer rank
4.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.1 |
| quality rank | 7.7 |
| growth rank | 2.9 |
- ▸Superior ROE vs peers
Technical
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.9 |
| 52w position | 6.5 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.3 |
| days to cover | 8.1 |
| volatility | 4.2 |
| put call | 7.9 |
| implied vol | 4.3 |
| beta | 5.9 |
| debt equity | 4.0 |
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (6)
- MOMENTUM:7.7>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:21d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.5<1.5@spot
Warning (2)
- DEATH_CROSS:momentum=7.7>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.50
Upside
+7.4%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 77
EdgeCatalyst-Driven — Earnings in 21d with 4/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:7.7>=5.5. Top dim: Momentum at 7.7; weakest: Technical at 2.5. No conviction either direction.
The strongest dimensions are Momentum at 7.7, Catalyst at 7.6, and Value at 7.1; the weakest are Technical at 2.5, Peer rank at 4.4, and Insider at 5.0. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.50 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Exceptional Earnings Beat Streak
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, breaking the current 4-quarter positive beat streak.
- P2Managed Care Payer Concentration
Trip ifManaged care payer revenue grows to more than 75% of total revenue, indicating concentration is worsening rather than diversifying.
- P3Strong Cash Generation Quality
Trip ifFree cash flow as a percentage of net income drops below 80% in any reported 12-month period, signaling the cash conversion advantage has structurally deteriorated.
- P4Analyst Upside Margin Of Safety
Trip ifStock price falls below $155, more than 13% below the current $179.11, confirming the recovery pattern has failed and the downtrend has resumed.